Dinaciclib, a cyclin-dependent kinase inhibitor, is a substrate of human ABCB1 and ABCG2 and an inhibitor of human ABCC1 in vitro
D Cihalova, M Ceckova, R Kucera, J Klimes… - Biochemical …, 2015 - Elsevier
Dinaciclib is a novel cyclin-dependent kinase inhibitor (CDKI) with significant activity against
various cancers in vitro and in vivo. ABC efflux transporters play an important role in drug …
various cancers in vitro and in vivo. ABC efflux transporters play an important role in drug …
Interactions of cyclin-dependent kinase inhibitors AT-7519, flavopiridol and SNS-032 with ABCB1, ABCG2 and ABCC1 transporters and their potential to overcome …
D Cihalova, F Staud, M Ceckova - Cancer chemotherapy and …, 2015 - Springer
Purpose ATP-binding cassette (ABC) transporters play an important role in multidrug
resistance (MDR) toward anticancer drugs. Here, we evaluated interactions of cyclin …
resistance (MDR) toward anticancer drugs. Here, we evaluated interactions of cyclin …
Purvalanol A, olomoucine II and roscovitine inhibit ABCB1 transporter and synergistically potentiate cytotoxic effects of daunorubicin in vitro
D Cihalova, J Hofman, M Ceckova, F Staud - PLoS One, 2013 - journals.plos.org
Cyclin-dependent kinase inhibitors (CDKi) have high potential applicability in anticancer
therapy, but various aspects of their pharmacokinetics, especially their interactions with drug …
therapy, but various aspects of their pharmacokinetics, especially their interactions with drug …
Role of breast cancer resistance protein (BCRP, ABCG2) in cancer outcomes and drug resistance
K Natarajan, MR Baer, DD Ross - … to targeted ABC transporters in cancer, 2015 - Springer
The breast cancer resistance protein (BCRP), formally known as ATP-binding cassette
protein G2 (ABCG2), is an efflux transporter that plays a significant role in altering …
protein G2 (ABCG2), is an efflux transporter that plays a significant role in altering …
Placental passage of olomoucine II, but not purvalanol A, is affected by p-glycoprotein (ABCB1), breast cancer resistance protein (ABCG2) and multidrug resistance …
J Hofman, R Kučera, Z Neumanova, J Klimes… - Xenobiotica, 2016 - Taylor & Francis
Purine cyclin-dependent kinase inhibitors have recently been recognised as promising
candidates for the treatment of various cancers. While pharmacodynamic properties of these …
candidates for the treatment of various cancers. While pharmacodynamic properties of these …
Studium interakcí nových protinádorových léčiv s lékovými transportéry
A Šorf - 2019 - dspace.cuni.cz
Univerzita Karlova, Farmaceutická fakulta v Hradci Králové Katedra farmakologie a
toxikologie Kandidát: Mgr. Aleš Šorf Školitel: doc. PharmDr. Martina Čečková, Ph. D. Název …
toxikologie Kandidát: Mgr. Aleš Šorf Školitel: doc. PharmDr. Martina Čečková, Ph. D. Název …
Effects of Purvalanol A on Imatinib-Sensitive and-Insensitive Chronic Myeloid Leukaemia Cell Lines
P Phoomvuthisarn - 2015 - livrepository.liverpool.ac.uk
Objectives: This project aimed to investigate effects of purvalanol A on imatinib-sensitive and-
insensitive chronic myeloid leukaemia (CML) cell lines, and normal white blood cells …
insensitive chronic myeloid leukaemia (CML) cell lines, and normal white blood cells …